Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs

Seminars in Dialysis

Volumn 23, Issue 3, 2010, Pages 239-243

  Jones, Glenville ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL; DRUG DERIVATIVE; VITAMIN D;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; HUMAN; RENAL REPLACEMENT THERAPY; RISK FACTOR; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; KIDNEY FAILURE, CHRONIC;

CALCITRIOL; CHOLECALCIFEROL; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77955135389     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00722.x     Document Type: Article

References (34)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
2. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels & extra-renal 1α-hydroxylase in the classical and non-classical actions of 1α,25-dihydroxyvitamin D3. Semin Dial 2007, 20:316-324.
3. Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M. Vitamin D, beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med 2009, 179:630-636.
4. Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996, 11:22-28.
5. Goodman WG, Coburn JW, Slatopolsky E, Salusky IB, Quarles LD. Chapter 74: Renal osteodystrophy in adults and children. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2003, 430-447. Favus M, ed, 5th edn, Washington, DC, Amer Soc Bone Min Res, Washington DC
6. Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Nissel R, Wernecke K-D, Andreae J, Haffner D, Querfeld U. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol Dial Transplant 2006, 21:1906-1914.
7. Fournier A, Harbouche L, Mansour J, Shahapuni I. Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset end stage renal disease. Nephrol Dial Transplant 2007, 22:956-957.
8. Jones G, Strugnell S, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998, 78:1193-1231.
9. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers and cardiovascular disease. Am J Clin Nutr 2004, 80(Suppl.):1678S-1688S.
10. Liu PT, Stenger S, Li H. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
11. Baeke F, Etten EV, Overbergh L, Mathieu C. Vitamin D3 and the immune system: maintaining the balance in health and disease. Nutr Res Rev 2007, 20:106-118.
12. Masuda S, Jones G. The promise of vitamin D analogs in the treatment of hyperproliferative conditions. Mol Cancer Ther 2006, 5:797-808.
13. Ren S, Nguyen L, Wu S, Encinas C, Adams JS, Hewison M. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem 2005, 280:20604-20611.
14. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21:353-361.
15. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004, 24:503-510.
16. Michaud J, Naud J, Demers C, Petit JL, Ouimet D, Leblond F, Gascon-Barre M, Pichette V. Downregulation of calcidiol synthesis in chronic renal failure rats. J Amer Soc Nephrol 2009, 20. TH-P0627 (Abs), sb
17. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008, 118:3820-3828.
18. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK. 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005, 289:G1036-G1042.
19. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31-38.
20. Wolf M. Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens 2009, 18:463-468.
21. KDOQI clinical practise guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42(Suppl. 3):S1-S202.
22. Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007, 50:59-68.
23. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007, 27:36-43.
24. Park EA. The therapy of rickets. JAMA 1940, 94:370-379.
25. Roborgh JR, de Man T. The hypercalcemic activity of dihydrotachysterol-2 and dihydrotachysterol-3 and of the vitamins D2 and D3: comparative experiments in rats. Biochem Pharmacol 1960, 2:1-6.
26. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004, 89:5387-5391.
27. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008, 88:582S-586S.
28. Jones G, Horst RL, Carter G, Makin HLJ. Contemporary diagnosis and treatment of vitamin D-related disorders. J Bone Mineral Res 2007, 22(Suppl. 2):V11-V15.
29. Carter GD. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin Chem 2009, 55:1300-1302.
30. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004, 29:664-673.
31. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008, 19:1509-1519.
32. Wang TJ, Pencina MJ, Booth SL. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
33. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci 2009, 338:40-44.
34. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009, 75:88-95.